Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Dimitri Poddighe,1,2 Elena Kovzel2 1Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan, 010000, Kazakhstan; 2Clinical Academic Department of Pediatrics, University Medical Center (UMC), Nur-Sultan, 010000, KazakhstanCorrespondence: Dimitri Poddighe Email dimitri.poddighe@nu...

Full description

Bibliographic Details
Main Authors: Poddighe D, Kovzel E
Format: Article
Language:English
Published: Dove Medical Press 2021-12-01
Series:Journal of Inflammation Research
Subjects:
covid-19
sars-cov-2
omalizumab
dupilumab
benralizumab
mepolizumab
reslizumab
asthma
chronic spontaneous urticaria
biologics
Online Access:https://www.dovepress.com/impact-of-anti-type-2-inflammation-biologic-therapy-on-covid-19-clinic-peer-reviewed-fulltext-article-JIR

Internet

https://www.dovepress.com/impact-of-anti-type-2-inflammation-biologic-therapy-on-covid-19-clinic-peer-reviewed-fulltext-article-JIR

Similar Items